🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Grenoble
NCT05704881 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Although we know that these numbers are underestimated, Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease that affects between 8 and 12% of adults. According to a 2020 WHO report, it is the third most common cause of mortality in developed countries. This disease is punctuated by exacerbations associated with an 8% mortality of hospitalized patients, increased to 24% when the patient is admitted to intensive care unit. Early detection and treatment of these exacerbations appears to be essential to improve patient survival. End-tidal carbon dioxide (EtCO2) is used to assess a patient's respiratory and hemodynamic status. Indeed, EtCO2 is a non-invasive measure that could allow the estimation of arterial carbon dioxide (PaCO2) without performing blood gases, an arterial blood sampling, classically at the radial artery. This study aimed to find an EtCO2 va

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * All patient presenting to the emergency department with acute dyspnea and with a history of COPD documented or reported by the patient and/or family * Male or female≥18 years old who did not oppose to participating in the study Exclusion Criteria: * Hypotension (SBP \< 90 mmHg or MBP \< 65 mmHg) * Patient already included in the study during a previous visit to the emergency department * Patient already ventilated with invasive or NIV during admission to the emergency department * COPD exacerbation rejected after medical and additional examinations * Non-communicative or non-French speaking patients, or with impaired comprehension, or with impaired consciousness * Protected persons referred to in articles L1121-6 and L1121-8 of French public health code (deprived of liberty, tutorship or curatorship)
💊

What it tests

  • End-Tidal CO2 measurement during COPD exacerbation
📍

Where

2 sites
CHU Grenoble Alpes
Grenoble, France
Hospices Civils de Lyon
Lyon, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy